Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond
CompanyDrug

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

AbbVie Inc. (NYSE: ABBV) announced the official launch in China of Epkinly (epcoritamab), a CD3×CD20 bispecific antibody, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma…

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal
CompanyDeals

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

CompanyDrug

Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC

CompanyDeals

Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio

CompanyDrug

BeOne’s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL/SLL and MCL

Hengrui's HRS9531 and AR‑PROTAC Win NMPA IND Approval for Clinical Trials
CompanyDrug

Hengrui’s HRS9531 and AR‑PROTAC Win NMPA IND Approval for Clinical Trials

Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets
CompanyDeals

Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets

Humanwell Healthcare's HW221043 Receives NMPA Approval for Advanced Solid Tumor Trials
CompanyDrug

Humanwell Healthcare’s HW221043 Receives NMPA Approval for Advanced Solid Tumor Trials

Show More